American Century Companies Portfolio holdings
American Century Companies, Inc., founded in 1958 by James E. Stowers Jr. as Twentieth Century Mutual Funds and headquartered in Kansas City, Missouri, is a privately held investment management firm renowned for its focus on delivering investment results to clients while supporting medical research. Starting with just $100,000 from 24 shareholders, it rebranded to American Century Investments in 1997 and now manages hundreds of billions in assets across mutual funds, ETFs, and institutional portfolios, emphasizing no-load funds and a client-centric approach. The firm’s unique ownership structure sees over 40% of its profits funneled to the Stowers Institute for Medical Research, which it majority-owns, funding groundbreaking biomedical research, while Nomura Holdings holds a significant minority stake. With a global presence in cities like New York, London, and Hong Kong, and a workforce of around 1,400, American Century blends financial expertise with a mission to improve lives through both wealth creation and scientific advancement.
Top Buys
| 1 |
Salesforce
CRM
|
+$306M |
| 2 |
Church & Dwight Co
CHD
|
+$182M |
| 3 |
Lattice Semiconductor
LSCC
|
+$165M |
| 4 |
UnitedHealth
UNH
|
+$157M |
| 5 |
Meta Platforms (Facebook)
META
|
+$149M |
Top Sells
| 1 |
Humana
HUM
|
+$292M |
| 2 |
iShares Russell Mid-Cap Value ETF
IWS
|
+$265M |
| 3 |
Air Products & Chemicals
APD
|
+$200M |
| 4 |
HES
Hess
HES
|
+$191M |
| 5 |
Idexx Laboratories
IDXX
|
+$182M |
Sector Composition
| 1 | Technology | 24.43% |
| 2 | Financials | 13.47% |
| 3 | Healthcare | 12.47% |
| 4 | Consumer Discretionary | 12.31% |
| 5 | Industrials | 10.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2701
ESSA Pharma
EPIX
$9.6M
| $132K | ﹤0.01% |
+20,044
| New | +$132K |
|
2702
Zegna
ZGN
$2.22B
| $132K | ﹤0.01% |
11,413
| – | – |
|
2703
SGHC Ltd
SGHC
$6.39B
| $130K | ﹤0.01% |
41,161
-105,221
| -72% | -$334K |
|
2704
Codexis
CDXS
$219M
| $130K | ﹤0.01% |
42,749
+14,748
| +53% | +$45K |
|
2705
Custom Truck One Source
CTOS
$1.29B
| $130K | ﹤0.01% |
21,093
+8,080
| +62% | +$49.9K |
|
2706
Sight Sciences
SGHT
$181M
| $129K | ﹤0.01% |
24,934
+9,026
| +57% | +$46.6K |
|
2707
Erasca
ERAS
$443M
| $129K | ﹤0.01% |
60,334
+19,924
| +49% | +$42.4K |
|
|
VTNR
2708
DELISTED
Vertex Energy, Inc
VTNR
| $128K | ﹤0.01% |
+37,849
| New | +$128K |
|
2709
Sabre
SABR
$738M
| $127K | ﹤0.01% |
28,977
-25,315
| -47% | -$111K |
|
2710
89bio
ETNB
$1.2B
| $127K | ﹤0.01% |
+11,363
| New | +$127K |
|
2711
Ribbon Communications
RBBN
$676M
| $126K | ﹤0.01% |
43,396
+3,903
| +10% | +$11.3K |
|
|
ACCD
2712
DELISTED
Accolade, Inc. Common Stock
ACCD
| $125K | ﹤0.01% |
10,397
-10,930
| -51% | -$131K |
|
2713
TScan Therapeutics
TCRX
$99.9M
| $124K | ﹤0.01% |
21,315
+2,103
| +11% | +$12.3K |
|
2714
Janux Therapeutics
JANX
$1.45B
| $123K | ﹤0.01% |
+11,443
| New | +$123K |
|
2715
Ponce Financial Group
PDLB
$336M
| $123K | ﹤0.01% |
12,555
+2,117
| +20% | +$20.7K |
|
2716
Zevra Therapeutics
ZVRA
$435M
| $122K | ﹤0.01% |
18,683
+1,004
| +6% | +$6.58K |
|
|
INZY
2717
DELISTED
Inozyme Pharma
INZY
| $122K | ﹤0.01% |
28,695
+10,622
| +59% | +$45.3K |
|
|
RDNW
2718
RideNow Group, Inc. Class B Common Stock
RDNW
$156M
| $121K | ﹤0.01% |
+14,895
| New | +$121K |
|
|
SOL
2719
Emeren Group
SOL
$96.5M
| $121K | ﹤0.01% |
44,262
-3,379
| -7% | -$9.23K |
|
2720
The Honest Company
HNST
$447M
| $119K | ﹤0.01% |
+36,038
| New | +$119K |
|
|
API
2721
Agora
API
$343M
| $118K | ﹤0.01% |
44,747
+1,434
| +3% | +$3.77K |
|
2722
Axogen
AXGN
$755M
| $115K | ﹤0.01% |
+16,902
| New | +$115K |
|
2723
Verrica Pharmaceuticals
VRCA
$44.9M
| $115K | ﹤0.01% |
1,570
+42
| +3% | +$3.08K |
|
2724
Five Point Holdings
FPH
$417M
| $114K | ﹤0.01% |
37,239
-209
| -0.6% | -$642 |
|
2725
Ranpak Holdings
PACK
$395M
| $114K | ﹤0.01% |
19,592
+3,871
| +25% | +$22.5K |
|